RELX-INTERNATIONAL
17.5.2022 15:16:11 CEST | Business Wire | Press release
RELX International, a responsible multinational electronic cigarettes company, is continuing its support for the Hashemite Kingdom of Jordan to adopt a more favourable fiscal policy when it comes to the country’s e-cigarette polices and taxes. Should policies and taxes on these products be revised in line with regional markets such as Egypt, Kuwait, Saudi Arabia and the UAE, Jordanian adult smokers, the business environment and government financial reserves will benefit greatly.
According to the Jordan National Stepwise Survey (STEPs) for Noncommunicable Diseases Risk Factors 2019, adult smokers in Jordan smoke an average of 21.3 cigarettes a day [1]. The rate is said to be amongst the highest in the world, with worldwide scientific research linking high tobacco use to a raft of diseases. In contrast, an increasing number of reputed organisations including the UK’s National Health Service (NHS) has said that e-cigarettes are far less harmful than traditional cigarettes, and can actually help smokers reduce or quit smoking altogether [2].
For adult smokers in Jordan, reforming e-cigarette policies and reducing taxes will bring legal access to accessibly priced, premium quality e-cigarette products, which are backed by the latest research & development. Responsible brands will also be able to work closer with their partners to educate adult consumers about the risks and benefits of their products, and restrict access to minors. Consumers can also rest assured that regulated products have been signed off by the Jordanian Food and Drug Administration, which is the sole national competent authority for drug safety & efficacy and food safety & quality.
While e-cigarette products do contain nicotine and so are not completely without risks, the latter is not the main cause of smoking-related diseases according to various regulatory and health organisations including the aforementioned NHS. In fact, a research paper published on the website ‘Tobacco Control’ has stated that the replacement of combustible cigarettes by e-cigarettes use over a 10-year period yields 6.6-million fewer premature deaths, with 86.7-million fewer life years lost in the Optimistic Scenario in the United States alone [3].
Apart from the benefit to adult smokers in the country, broad e-cigarette reforms will benefit the business and investment environment in Jordan. E-cigarette vendors will be attracted to investing in on-ground facilities to better liaise with the market, while the supply chain responsible for the distribution of products could also experience significant growth; traditionally, e-cigarette products are retailed by small- and medium-businesses, and the legalisation of these products with balanced taxation will attract entrepreneurs keen to set up new retail points across the country.
Through these important reforms, Jordanian authorities will also benefit from the collection of tax revenues from legally imported products. In line with this, authorities will be able to clamp down on tax evasion issues associated with illegal market players, while simultaneously working to curtail the spread of inferior and dangerous black-market products, which do not meet the standards and regulations outlined by local and international authorities. This will positively impact the safety of adult smokers who will be able to access licensed and standard-compliant e-cigarette products at an accessible price.
Links:
[1] Jordan National Stepwise Survey (STEPs) for Noncommunicable Diseases Risk Factors 2019
[2] NHS UK - Using e-cigarettes to stop smoking
[3] Tobacco Control – Potential deaths averted in USA by replacing cigarettes with e-cigarettes
Notes to Editors:
About RELX International
Founded in 2019, RELX International is a multinational electronic cigarettes company that markets and sells RELX, The world’s advanced vape brand powered by SuperSmoothTM technology. RELX, Asia’s leading e-cigarette brand, is widening its footprint across the world, and is currently available in 40+ countries such as the UK, France, Italy, Germany, Indonesia, Philippines, Canada, KSA and the UAE. What sets RELX apart from competition is the fact that it has a full ecosystem (such as closed pods, disposables, device, and power bank accessories) that are designed at a cutting-edge research and development center and produced at one of the world’s largest e-cigarette factories. RELX's mission is to make RELX a trusted brand for legal age adult smokers through state-of-the-art products, industry-leading technologies, and scientific advances in collaboration with talented and committed people around the globe. The company has attracted global talents from Uber, Procter & Gamble, Apple, Beats, and L'Oréal. RELX is proud to be listed in Dubai Duty Free, the first duty free channel in the world.
RELX's Social Media
LinkedIn: RELX International
Instagram: @RELXArabia
Facebook: @RELXArabia
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005655/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
